Select publications

Publications discussed by Dr Carlson

The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Coombes CD et al. Under-reporting of symptoms in patients with early breast cancer (EBC) who have received tamoxifen treatment for 2-3 years. Proc ASCO 2003;Abstract 48.

Goodwin PJ et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001;345:1719-26. Abstract

National Comprehensive Cancer Network (NCCN®). NCCN Clinical Practice Guidelines in Oncology, Breast Cancer — Version 2. 2003. Available at http://www.nccn.org/physician_gls/f_guidelines.html.

Spiegel D et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;2(8668):888-91. Abstract

Winer EP et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor–positive breast cancer: Status report 2002. J Clin Oncol 2002;20:3317-27. Abstract

Winer EP et al. American Society of Clinical Oncology Technology Assessment Working Group Update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21:2597-9. Abstract

Role of gefitinib in breast cancer

Arteaga CL et al. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 2002;29(3 Suppl 11):4-10. Abstract

Baselga J. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: A promising strategy ready for clinical testing. Ann Oncol 2002;13(1):8-9. Abstract

Ciardiello F et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002;98(3):463-9. Abstract

Khalil MY et al. Targeting epidermal growth factor receptor: Novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 2003;3(3):367-80. Abstract

Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Abstract

Moasser MM et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61(19):7184-8. Abstract

Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat 2002;75(Suppl 1):51-5; discussion 57-9. Abstract

Moulder SL et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61(24):8887-95. Abstract

Nicholson RI et al. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen receptor-positive breast cancer. Ann N Y Acad Sci 2002;963:104-15. Abstract

Normanno N et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13(1):65-72. Abstract

Ranson M. ZD1839 (Iressa): For more than just non-small cell lung cancer. Oncologist 2002;7(Suppl 4):16-24. Abstract

Robertson JFR et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Proc ASCO 2003;Abstract 23.

Home · Search